Navigation Links
In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
Date:3/18/2009

Telaprevir in Combination with a Long-Acting Interferon and Ribavirin Will Earn Decision Resources' Clinical Gold Standard for Hepatitis C Virus in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., March 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists and hepatologists identify a therapy's effect on sustained virologic response in genotype 1 patients as the attribute that most influences their prescribing decisions in hepatitis C virus infection. Clinical data and the opinions of interviewed thought leaders indicate that the addition of Vertex/Janssen Pharmaceutica/Mitsubishi Tanabe's telaprevir or Schering-Plough's boceprevir to peginterferon/ribavirin provide advantages in this attribute over Roche's Pegasys (peginterferon-a-2a) plus ribavirin, the sales-leading treatment in the market.

The new report entitled Hepatitis C Virus: Protease and Polymerase Inhibitors on the Horizon to Revolutionize Treatment finds that a novel protease inhibitor that, when used in combination with peginterferon/ribavirin and achieves a significantly higher sustained virologic response in genotype 1 patients with only 24 weeks of treatment compared with the standard 48-week therapy with peginterferon/ribavirin, would earn a higher patient share in the United States than in Europe. The report finds that such an agent would earn a 60 percent patient share in the U.S. and a 40 percent patient share in Europe, according to surveyed U.S. and European gastroenterologists and hepatologists.

In 2008, Decision Resources' proprietary clinical gold standard for hepatitis C virus was Pegasys plus ribavirin because of its advantages in delivery and dosing. Based on available data and expert opinion, telaprevir plus ribavirin and a long-acting interferon will earn gold-standard status for hepatitis C virus following approval of telaprevir in 2011.

"New regimens that include a protease inhibitor, such as telaprevir or boceprevir, appear to have a competitive advantage in efficacy in patients infected with genotype 1 over the current peginterferon/ribavirin regimens," said Decision Resources Vice President John Lebbos, M.D. "Furthermore, the duration of therapy for genotype 1 patients can potentially be reduced with new three-drug regimens."

About the Report

Hepatitis C Virus: Protease and Polymerase Inhibitors on the Horizon to Revolutionize Treatment is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Decision Resources                       Decision Resources, Inc.
    Christopher Comfort                      Elizabeth Marshall
    781-296-2597                             781-296-2563
    ccomfort@dresources.com                  emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is telmisartan effective in treating non-alcoholic steatohepatitis?
2. Varicella zoster infection causes severe autoimmune hepatitis
3. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
4. Liver transplant recipients with hepatitis B may need lifelong antiviral treatment
5. Pitt receives $11 million from NIH to coordinate hepatitis B clinical research network
6. PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine
7. Hispanics Respond Poorly to Standard Hepatitis C Therapy
8. May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?
9. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
10. Hepatitis C treatment reduces the virus but liver damage continues
11. Improved Testing for Hepatitis B Virus From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance and financial planning ... the Cape Coral area, is embarking on a charity drive with the goal of ... The Harry Chapin Food Bank of Southwest Florida works to provide fresh and nutritious ...
(Date:12/8/2016)... ... December 08, 2016 , ... Bill Mull Agencies, a ... in and around central Kansas, is joining the Youth Horizons organization for a ... , Headquartered in Wichita, Youth Horizons works to empower area children from unstable, ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and mental ... mental health systems reform legislation in more than fifty years. We applaud the ... of our elected officials to improving mental health services and supports in our ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a ... smoothing and tightening the skin of the face to create more youthful features. ... with very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 million (net ... Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... , Dec. 8, 2016 Bodycad announced ... for improving the accuracy, reproducibility and speed for ... long and small bone orthopaedic applications. These patents ... creating personalized orthopaedic restorations based on each patient,s ... restorations, the company harnesses the world,s first suite ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
Breaking Medicine Technology: